248 related articles for article (PubMed ID: 29769258)
21. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
Bowler E; Porazinski S; Uzor S; Thibault P; Durand M; Lapointe E; Rouschop KMA; Hancock J; Wilson I; Ladomery M
BMC Cancer; 2018 Apr; 18(1):355. PubMed ID: 29606096
[TBL] [Abstract][Full Text] [Related]
23. Regulation of influenza A virus mRNA splicing by CLK1.
Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
[TBL] [Abstract][Full Text] [Related]
24. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.
Shi Y; Park J; Lagisetti C; Zhou W; Sambucetti LC; Webb TR
Bioorg Med Chem Lett; 2017 Feb; 27(3):406-412. PubMed ID: 28049589
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase clk/STY is differentially regulated during erythroleukemia cell differentiation: a bias toward the skipped splice variant characterizes postcommitment stages.
García-Sacristán A; Fernández-Nestosa MJ; Hernández P; Schvartzman JB; Krimer DB
Cell Res; 2005 Jul; 15(7):495-503. PubMed ID: 16045812
[TBL] [Abstract][Full Text] [Related]
26. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.
Liu S; Marneth AE; Alexe G; Walker SR; Gandler HI; Ye DQ; Labella K; Mathur R; Toniolo PA; Tillgren M; Gokhale PC; Barbie D; Mullally A; Stegmaier K; Frank DA
Blood Adv; 2018 Dec; 2(23):3428-3442. PubMed ID: 30504235
[TBL] [Abstract][Full Text] [Related]
27. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy.
Sako Y; Ninomiya K; Okuno Y; Toyomoto M; Nishida A; Koike Y; Ohe K; Kii I; Yoshida S; Hashimoto N; Hosoya T; Matsuo M; Hagiwara M
Sci Rep; 2017 May; 7():46126. PubMed ID: 28555643
[TBL] [Abstract][Full Text] [Related]
28. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
[TBL] [Abstract][Full Text] [Related]
29. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.
Martín Moyano P; Němec V; Paruch K
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066143
[TBL] [Abstract][Full Text] [Related]
30. SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.
Tiek D; Wells CI; Schröder M; Song X; Alamillo-Ferrer C; Goenka A; Iglesia R; Lu M; Hu B; Kwarcinski F; Sintha P; de Silva C; Hossain MA; Picado A; Zuercher W; Zutshi R; Knapp S; Riggins RB; Cheng SY; Drewry DH
Curr Res Chem Biol; 2023; 3():. PubMed ID: 38009092
[TBL] [Abstract][Full Text] [Related]
31. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
32. Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy.
Wong R; Balachandran A; Mao AY; Dobson W; Gray-Owen S; Cochrane A
Retrovirology; 2011 Jun; 8():47. PubMed ID: 21682887
[TBL] [Abstract][Full Text] [Related]
33. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
34. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells.
Eisenreich A; Bogdanov VY; Zakrzewicz A; Pries A; Antoniak S; Poller W; Schultheiss HP; Rauch U
Circ Res; 2009 Mar; 104(5):589-99. PubMed ID: 19168442
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion.
Liu Y; Conaway L; Rutherford Bethard J; Al-Ayoubi AM; Thompson Bradley A; Zheng H; Weed SA; Eblen ST
Nucleic Acids Res; 2013 May; 41(9):4949-62. PubMed ID: 23519612
[TBL] [Abstract][Full Text] [Related]
36. Disordered protein interactions for an ordered cellular transition: Cdc2-like kinase 1 is transported to the nucleus via its Ser-Arg protein substrate.
George A; Aubol BE; Fattet L; Adams JA
J Biol Chem; 2019 Jun; 294(24):9631-9641. PubMed ID: 31064840
[TBL] [Abstract][Full Text] [Related]
37. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution.
Colwill K; Pawson T; Andrews B; Prasad J; Manley JL; Bell JC; Duncan PI
EMBO J; 1996 Jan; 15(2):265-75. PubMed ID: 8617202
[TBL] [Abstract][Full Text] [Related]
38. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
39. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.
Koh CM; Bezzi M; Low DH; Ang WX; Teo SX; Gay FP; Al-Haddawi M; Tan SY; Osato M; Sabò A; Amati B; Wee KB; Guccione E
Nature; 2015 Jul; 523(7558):96-100. PubMed ID: 25970242
[TBL] [Abstract][Full Text] [Related]
40. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM; Dickson RB
Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
